Journal: Cancer Gene Therapy

Article Title: Serum small extracellular vesicles-derived BST2 as a biomarker for papillary thyroid microcarcinoma promotes lymph node metastasis

doi: 10.1038/s41417-024-00854-9

Figure Lengend Snippet: A Venn diagram of differentially expressed proteins from different comparisons. B BST2 levels according to proteomic analysis ( n = 10 for NLNM-sEVs and LNM-sEVs; *BN-sEVs vs. other groups, * P < 0.05, **** P < 0.0001; # NLNM-sEVs vs. LNM-sEVs, ## P < 0.01). C Western blot analysis showed BST2 levels in serum sEVs ( n = 3 for BN-sEVs, NLNM-sEVs, and LNM-sEVs, *BN-sEVs vs. other groups, ** P < 0.01, *** P < 0.001; # NLNM-sEVs vs. LNM-sEVs, # P < 0.05); Flotillin-1 as sEVs protein marker was used as the control. D ELISA results revealed BST2 protein concentrations in serum sEVs of the validation cohort (** P < 0.01, **** P < 0.0001). E ROC curve analysis of the sensitivity, specificity, and AUC of serum sEVs BST2 level in the validation cohort. The T refers to the whole group of PTMC samples (LNM and NLNM). Error bars represent standard deviations.

Article Snippet: A BST2 polyclonal antibody (1:200, Proteintech, 13560-1-AP) was used to visualize BST2 expression via an IHC assay.

Techniques: Western Blot, Marker, Control, Enzyme-linked Immunosorbent Assay, Biomarker Discovery

Journal: Cancer Gene Therapy

Article Title: Serum small extracellular vesicles-derived BST2 as a biomarker for papillary thyroid microcarcinoma promotes lymph node metastasis

doi: 10.1038/s41417-024-00854-9

Figure Lengend Snippet: A The proliferation rate of BCPAP cells was downregulated after the knockdown of BST2 (* P < 0.05, ** P < 0.01). B The cell migration of BCPAP cells was downregulated after the knockdown of BST2 (*** P < 0.001). NC: negative control. C The proliferation rate of BCPAP cells was upregulated after overexpression of BST2 (** P < 0.01, *** P < 0.001, **** P < 0.0001). D The cell migration of BCPAP cells was upregulated after overexpression of BST2 (**** P < 0.0001). E , F The morphology and size of BCPAP-derived sEVs were determined by TEM and NTA; scale bar: 100 nm. G SEVs markers CD81, CD63, ALIX, Calnexin, and sEVs BST2 levels were measured using western blot. H Lymph tube formation response to OE-BST2 sEVs is determined (*** P < 0.001). I–J The cell migration and proliferation of HLEC cells in response to OE-BST2 sEVs are shown (* P < 0.05, ** P < 0.01, **** P < 0.0001). Error bars represent standard deviations.

Article Snippet: A BST2 polyclonal antibody (1:200, Proteintech, 13560-1-AP) was used to visualize BST2 expression via an IHC assay.

Techniques: Knockdown, Migration, Negative Control, Over Expression, Derivative Assay, Western Blot

Journal: Cancer Gene Therapy

Article Title: Serum small extracellular vesicles-derived BST2 as a biomarker for papillary thyroid microcarcinoma promotes lymph node metastasis

doi: 10.1038/s41417-024-00854-9

Figure Lengend Snippet: A Representative gross anatomical image of the lower limb of a nude mouse with footpad tumor (left arrow) and metastatic popliteal lymph node (right arrow). B Images of the popliteal lymph nodes in control-sEVs-BCPAP or BST2-sEVs-BCPAP groups ( n = 12). C Statistical comparison of the volume of popliteal lymph nodes in each group ( n = 12, ** P < 0.01). D Representative images of HE staining and BST2 IHC staining for popliteal lymph nodes in each group with different magnifications. Scale bars: 100 μm for the 10 × magnified images and 50 μm for the 20 × magnified images. E The IHC staining was assessed as the sum of the percentage and intensity scores (* P < 0.05). Error bars represent standard deviations.

Article Snippet: A BST2 polyclonal antibody (1:200, Proteintech, 13560-1-AP) was used to visualize BST2 expression via an IHC assay.

Techniques: Control, Comparison, Staining, Immunohistochemistry

Journal: Scientific Reports

Article Title: Human Bone Marrow Endothelial Progenitor Cell Transplantation into Symptomatic ALS Mice Delays Disease Progression and Increases Motor Neuron Survival by Repairing Blood-Spinal Cord Barrier

doi: 10.1038/s41598-019-41747-4

Figure Lengend Snippet: Characteristics of disease outcomes in G93A mice receiving hBMEPCs at symptomatic stage. Transplanted ALS mice with cell dose of 1 × 10 6 at 4 weeks post-treatment ( A ) significantly maintained body weight, ( B ) better extended hindlimbs, ( C ) delayed loss in muscle strength, and ( D ) stayed longer on rotarod vs. media-injected mice. Notable beneficial effects on motor function were determined in G93A mice 2–3 weeks after cell transplantation. * p < 0.05, ** p < 0.01.

Article Snippet: Cryopreserved human bone marrow-derived endothelial progenitor cells (hBMEPCs) were purchased from CELPROGEN (Torrance, CA, USA).

Techniques: Injection, Transplantation Assay

Journal: Scientific Reports

Article Title: Human Bone Marrow Endothelial Progenitor Cell Transplantation into Symptomatic ALS Mice Delays Disease Progression and Increases Motor Neuron Survival by Repairing Blood-Spinal Cord Barrier

doi: 10.1038/s41598-019-41747-4

Figure Lengend Snippet: Immunocytochemical analysis of transplanted hBMEPCs in blood smears. For identification of transplanted hBMEPCs within blood circulation of treated mice, immunofluorescent staining with the human anti-vWF was performed in blood smears. ( A ) hBMEPCs were positive for vWF immunoexpression (red, arrowheads). A few cells did not express vWF (asterisk) likely due to damaging during smear preparation. ( B ) There was no detection of human cells by vWF marker in blood smears from media-treated mice (asterisks). ( C , C’) In blood smears from cell-treated ALS mice, some cells were identified with human vWF (red, arrowheads). Cells negative for vWF are noted by asterisks. The nuclei in all images are shown with DAPI. Scale bar in A is 20 µm and B-C’ is 50 µm.

Article Snippet: Cryopreserved human bone marrow-derived endothelial progenitor cells (hBMEPCs) were purchased from CELPROGEN (Torrance, CA, USA).

Techniques: Staining, Marker